African Pharmaceutical Review

12/11/2025

The World Advanced Manufacturing & Future Mobility Event (WAM Morocco) debuts in Casablanca, 20–22 January 2026, in association with GITEX Africa.

Endorsed by the Moroccan Ministry of Industry and Trade and partnered with CGEM and AMDIE, this landmark platform will expand Morocco’s industrial base, foster emerging sectors and drive sustainable growth.

From AI, quantum computing and 3D printing to blockchain, mixed reality and specialised showcases in future mobility, green energy, pharma and digital food, WAM Morocco positions the country as a competitive global manufacturing hub.
Visit www.wammorocco.com.

31/10/2025

Save the date: WAM Saudi is where industrial ambition will meet real-world impact from 15–17 Feb 2026 in Riyadh Front, Saudi Arabia.
Be there as the Kingdom’s advanced manufacturing, logistics and tech leaders come together to power Vision 2030.
WAM Saudi will be the ultimate launchpad for opportunity, innovation and serious business growth.
Register now at www.wamsaudi.com.

12/03/2025

SAHPRA has announced an urgent recall of Fertomid-50 tablets (batch no. GH21051) after Cipla South Africa detected out-of-specification levels of related substances during stability testing.

Fertomid-50, which contains clomiphene citrate, is a non-steroidal fertility drug that stimulates ovulation to aid pregnancy.

Cipla has instructed distributors, wholesalers, and retailers to stop selling or dispensing the affected batch, which is set to expire in October 2025.

11/02/2025

US FDA has approved key antibiotic combination for treatment against resistant strains.

Aztreonam and avibactam provides a unique and effective option against microbes that are resistant to many β-lactam antibiotics.

06/02/2025

Key African medicines regulatory authorities sign agreement to improve operational efficiency, ensuring authorized products and clinical trials comply with internationally recognized regulatory standards.

Read more: https://africanpharmaceuticalreview.com/topics/News/key-african-medicines-regulatory-authorities-sign-agreement-to-enhance-efficiency

24/01/2025

Another African country has formally ratified the African Medicines Agency (AMA) treaty, marking a significant milestone that now stands at 29 out of 55 AU member states supporting the Agency.

Learn more:

A total of 29 out of 55 AU countries have now ratified the Treaty.

30/11/2024

Innovative HIV medication demonstrates almost 100% efficacy in preventing new HIV infections.

Learn more:

Lenacapavir is a groundbreaking capsid inhibitor currently under investigation as a twice-yearly injection for preventing HIV infection.

09/11/2024

Biotechnology companies Synaffix BV and BigHat Biosciences have joined forces to create next-generation AI-driven biopharmaceuticals. This partnership brings together Synaffix's sophisticated antibody-drug conjugate (ADC) technology with BigHat's state-of-the-art, machine learning-based antibody design platform, with the goal of expediting the development of groundbreaking therapies for difficult-to-treat medical conditions.

The collaboration will result in development of next-generation antibody-drug conjugates.

07/11/2024

Bayer and Liveo Research have unveiled an innovative, eco-friendly blister packaging solution designed to cut the carbon footprint of conventional blister packaging by almost 40%. This sustainable advancement demonstrates the companies' dedication to environmental responsibility, providing the pharmaceutical industry with a more sustainable packaging option that maintains high performance standards.

The new solution cuts down carbon footprint of blister packaging by 38%.

29/10/2024

Organon has successfully acquired Dermavant Sciences in a deal valued at up to $1.2 billion. This acquisition includes Dermavant’s innovative cream, VTAMA 1%, a topical treatment designed to manage mild, moderate, and severe plaque psoriasis in adults.

Learn more:

The deal includes acquisition of Dermavant’s non-steroidal topical treatment, VTAMA cream.

12/10/2024

AstraZeneca is set to pay as much as $1.92 billion for a promising new lipid-lowering molecule.

Learn more:

In the deal AstraZeneca will make an upfront payment of $100 million to CSCP Pharmaceutical Group Ltd with the figure expected to rise to $1.92 billion.

12/10/2024

Major advancement in breast cancer treatment as Roche's new therapy receives FDA approval.

Learn more in the comments